![Margo Roberts](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Margo Roberts
Director/Miembro de la Junta en UNITY BIOTECHNOLOGY, INC. .
Fortuna: - $ al 31/05/2024
Cargos activos de Margo Roberts
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
UNITY BIOTECHNOLOGY, INC. | Director/Miembro de la Junta | 04/12/2018 | - |
Independent Dir/Board Member | 04/12/2018 | - | |
Appia Bio, Inc.
![]() Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | Director/Miembro de la Junta | 09/08/2022 | - |
Historial de carrera de Margo Roberts
Antiguos cargos conocidos de Margo Roberts.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
LYELL IMMUNOPHARMA, INC. | Director Técnico/Científico/I+D | 01/01/2019 | 01/01/2021 |
CELYAD ONCOLOGY SA | Director/Miembro de la Junta | 01/08/2018 | 06/08/2020 |
Independent Dir/Board Member | 01/08/2018 | 06/08/2020 | |
KITE PHARMA INC | Director Técnico/Científico/I+D | 01/08/2011 | 01/07/2018 |
University of Virginia | Corporate Officer/Principal | 01/01/1999 | 01/12/2011 |
Cell Genesys, Inc.
![]() Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Corporate Officer/Principal | 01/01/1990 | 01/12/1998 |
INSTIL BIO, INC. | Director/Miembro de la Junta | - | - |
Yale University | Corporate Officer/Principal | - | - |
Formación de Margo Roberts.
University of Leeds | Doctorate Degree |
Estadísticas
Internacional
Estados Unidos | 9 |
Reino Unido | 2 |
Bélgica | 2 |
Operativa
Director/Board Member | 4 |
Corporate Officer/Principal | 3 |
Chief Tech/Sci/R&D Officer | 2 |
Sectorial
Health Technology | 8 |
Consumer Services | 4 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 4 |
---|---|
CELYAD ONCOLOGY SA | Health Technology |
UNITY BIOTECHNOLOGY, INC. | Health Technology |
LYELL IMMUNOPHARMA, INC. | Health Technology |
INSTIL BIO, INC. | Health Technology |
Empresas privadas | 3 |
---|---|
Kite Pharma, Inc.
![]() Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |
Cell Genesys, Inc.
![]() Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
Appia Bio, Inc.
![]() Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | Health Technology |
- Bolsa de valores
- Insiders
- Margo Roberts
- Experiencia